AURKA and small cell lung carcinoma: Of these, the MYC pathway stands out since MYC is amplified in a significant (~20%) fraction of SCLC patients and appears to have higher sensitivity to certain newer targeted therapies, such as AURKA and BET inhibitors [81,82,83,84].